ArticleOncology letters2022

Study on the method to avoid infusion-site adverse events following chemotherapeutic treatment with epirubicin and fosaprepitant using immortalized human umbilical vein endothelial cells.

Miho Yamasaki et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.